RhumbLine Advisers
UBX

RhumbLine Advisers’s Unity Biotechnology UBX Stock Holding History

RhumbLine Advisers’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-129
Closed -$174 – 4330
2024
Q2 		$174 Hold
129
– – ﹤0.01% 4324
2024
Q1 		$211 Hold
129
– – ﹤0.01% 4215
2023
Q4 		$248 Hold
129
– – ﹤0.01% 4228
2023
Q3 		$309 Hold
129
– – ﹤0.01% 4253
2023
Q2 		$328 Buy
+129
New +$341 ﹤0.01% 4333
2021
Q2 		– Sell
-3,736
Closed -$224K – 3104
2021
Q1 		$224K Sell
3,736
-155
-4% -$10.6K ﹤0.01% 2802
2020
Q4 		$204K Buy
3,891
+260
+7% +$12.5K ﹤0.01% 2830
2020
Q3 		$126K Sell
3,631
-450
-11% -$28.5K ﹤0.01% 2825
2020
Q2 		$354K Buy
4,081
+417
+11% +$30.9K ﹤0.01% 2494
2020
Q1 		$213K Buy
3,664
+10
+0.3% +$630 ﹤0.01% 2553
2019
Q4 		$263K Buy
3,654
+44
+1% +$3.1K ﹤0.01% 2654
2019
Q3 		$220K Buy
3,610
+92
+3% +$6.51K ﹤0.01% 2717
2019
Q2 		$334K Buy
3,518
+399
+13% +$33.9K ﹤0.01% 2560
2019
Q1 		$253K Buy
3,119
+82
+3% +$9.3K ﹤0.01% 2631
2018
Q4 		$494K Buy
+3,037
New +$403K ﹤0.01% 2304

Other funds holding UBX

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

RhumbLine Advisers's UBX Position: Q3 2024 in Review

RhumbLine Advisers sold out of Unity Biotechnology (UBX) in Q3 2024, closing a stake of 129 shares — an estimated $174 sold.

RhumbLine Advisers first reported a position in UBX in Q4 2018 and held it in 15 quarters. The position peaked at $494K in Q4 2018. 38 funds tracked by Wall St. Rank hold UBX as of Q3 2024.

  • RhumbLine Advisers reported no remaining Unity Biotechnology position as of Q3 2024 after selling out during the quarter.
  • RhumbLine Advisers sold 129 Unity Biotechnology shares in Q3 2024, an estimated $174.
  • RhumbLine Advisers first reported a position in Unity Biotechnology in Q4 2018 and held it in 15 quarters.
  • RhumbLine Advisers's Unity Biotechnology position peaked at $494K in Q4 2018.
  • 38 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2024.

Based on RhumbLine Advisers's 13F filing for Q3 2024, filed 12 Nov 2024.